Danaher Corporation (DHR)vsGuardant Health Inc (GH)
DHR
Danaher Corporation
$196.22
-0.16%
HEALTHCARE · Cap: $125.93B
GH
Guardant Health Inc
$152.35
+5.75%
HEALTHCARE · Cap: $20.67B
Smart Verdict
WallStSmart Research — data-driven comparison
Danaher Corporation generates 2224% more annual revenue ($25.11B vs $1.08B). DHR leads profitability with a 16.0% profit margin vs -40.1%. DHR earns a higher WallStSmart Score of 66/100 (B-).
DHR
Strong Buy66
out of 100
Grade: B-
GH
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-66.7%
Fair Value
$117.88
Current Price
$196.22
$78.34 premium
Intrinsic value data unavailable for GH.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 59.7% YoY
Large-cap with strong market position
Reasonable price relative to book value
Generating 1.3B in free cash flow
Revenue surging 48.3% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
ROE of 7.6% — below average capital efficiency
0.0% earnings growth
ROE of -4584.0% — below average capital efficiency
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : DHR
The strongest argument for DHR centers on EPS Growth, Market Cap, Price/Book. Profitability is solid with margins at 16.0% and operating margin at 18.0%. PEG of 1.15 suggests the stock is reasonably priced for its growth.
Bull Case : GH
The strongest argument for GH centers on Revenue Growth, Debt/Equity. Revenue growth of 48.3% demonstrates continued momentum.
Bear Case : DHR
The primary concerns for DHR are P/E Ratio, Return on Equity.
Bear Case : GH
The primary concerns for GH are EPS Growth, Return on Equity, Free Cash Flow.
Key Dynamics to Monitor
DHR profiles as a mature stock while GH is a hypergrowth play — different risk/reward profiles.
GH carries more volatility with a beta of 1.59 — expect wider price swings.
GH is growing revenue faster at 48.3% — sustainability is the question.
DHR generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
DHR scores higher overall (66/100 vs 31/100), backed by strong 16.0% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Danaher Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are Life Sciences, Diagnostics, and Environmental & Applied Solutions.
Guardant Health Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Guardant Health, Inc., a precision oncology company, offers blood testing, data sets, and testing in the United States and internationally. The company is headquartered in Redwood City, California.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?